Kabi Awaits Melrose Park Fate As mAbxience Deal Closes
€455m Deal For 55% Stake In Biosimilars Business Closed 1 August
Executive Summary
Fresenius Kabi is pressing on with its ‘Vision 2026’ strategic growth initiatives, with the company wrapping up its acquisition of Insud Pharma’s bio unit mAbxience. However, it remains “to some degree output constrained,” which looks set to continue to impact operations, amid staff shortages.
You may also be interested in...
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Fresenius Files Tocilizumab Biosimilar With EMA
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.